Get started
ZHEJIANG HISUN PHARMACEUTICAL COZZ

ZHEJIANG HISUN PHARMACEUTICAL CO

8.56CNYD
−0.09−1.04%
At close at Mar 21, 09:16 GMT
CNY
No trades
See on Supercharts
Overview
Financials
News Discussions Technicals Forecast Seasonals

600267 fundamentals

Key facts

Market capitalization‪10.03 B‬CNY
Dividend yield (indicated)—
Price to earnings Ratio (TTM)—
Basic EPS (TTM)−0.03CNY
Founded1956
Employees (FY)‪8.06 K‬
CEOWei Hong Xiao
Websitehisunpharm.com
About

Zhejiang Hisun Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products as well as veterinary medicines. Its products include active pharmaceutical ingredients, anti-tumor, cardiovascular, anti-infective, and generic drugs. The company was founded in 1956 and is headquartered in Taizhou, China.

Ownership
‪‪1.15 B‬‬
Free Float shares
‪‪653.60 M‬‬ (56.71%)
Closely held shares
‪‪499.02 M‬‬ (43.29%)
Free Float shares
‪‪653.60 M‬‬ (56.71%)
Closely held shares
‪‪499.02 M‬‬ (43.29%)
Capital structure
Market cap
‪‪10.03 B‬‬
Debt
‪‪4.98 B‬‬
Minority interest
‪‪242.51 M‬‬
Cash & equivalents
‪‪1.48 B‬‬
Enterprise value
‪‪13.77 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪10.03 B‬‬
Price to earning ratio (P/E)
—
Price to sales ratio (P/S)
1.06x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
—
Price to sales ratio (P/S)
1.06x
Valuation ratios
‪0.00‬
‪0.30‬
‪0.60‬
‪0.90‬
‪1.20‬
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪0.00‬
‪6.00‬
‪12.00‬
‪18.00‬
‪24.00‬
P/E
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−36%‬
‪−24%‬
‪−12%‬
‪0%‬
‪12%‬
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪‪−900.00 M‬‬
‪0.00‬
‪‪900.00 M‬‬
‪‪1.80 B‬‬
‪‪2.70 B‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪0.00‬
‪‪700.00 M‬‬
‪‪1.40 B‬‬
‪‪2.10 B‬‬
‪‪2.80 B‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪700.00 M‬‬
‪‪1.40 B‬‬
‪‪2.10 B‬‬
‪‪2.80 B‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2023
Pharmaceutical Distribution
Anti-Infective Drugs
Cardiovascular Drugs
Anti-tumor Drugs
Antiparasitic and Veterinary Drugs
Import of Finished Drugs and Promotion of Imported Preparations
Other Drugs
Endocrine Drugs
Other Business
Other
By country
Period: 2023
China
Foreign

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
2018
2021
2022
2023
2024
‪0.00‬
‪‪3.50 B‬‬
‪‪7.00 B‬‬
‪‪10.50 B‬‬
‪‪14.00 B‬‬
Actual
Estimate
Earnings
Next:Mar 29, 2025
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪−0.63‬
‪−0.42‬
‪−0.21‬
‪0.00‬
‪0.21‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

Dividend summary
0.00%
Payout ratio (TTM)
Dividend yield TTM
0.00%
Last payment
—
Last ex-date
—
Dividend history
‪0.0%‬
‪0.4%‬
‪0.8%‬
‪1.2%‬
‪1.6%‬
2019
2020
2021
2022
2023
‪0.00‬
‪0.04‬
‪0.09‬
‪0.14‬
‪0.18‬
Dividends per share (FY)
Dividend yield (FY) %

Financial health

Financial position and solvency of the company

Debt level and coverage
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪0.00‬
‪‪1.60 B‬‬
‪‪3.20 B‬‬
‪‪4.80 B‬‬
‪‪6.40 B‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪3.00 B‬‬
‪‪6.00 B‬‬
‪‪9.00 B‬‬
‪‪12.00 B‬‬
Assets
Liabilities